Cardiovascular
Pipeline Moves: advancement prospects jump for cardiovascular gene therapy
This week on Pipeline Moves, we start off by looking at the positive topline data from a Phase II trial…
XyloCor reports positive data from refractory angina gene therapy trial
XyloCor Therapeutics has reported positive topline data from the Phase II portion of its Phase I/II EXACT clinical trial of…
IMA acquires multi-therapeutic clinical trials company in the US
The IMA Group (IMA) has acquired multi-therapeutic company Clinical Trials of America (CTA) in the US. This acquisition will bring…
89bio to initiate Phase III trials for pegozafermin in severe hypertriglyceridaemia
On January 4, 2023, 89bio announced plans to initiate a Phase III clinical trial investigating pegozafermin for patients with severe…
Influenza vaccination reduces the risk of stroke
Cardiovascular diseases (CVD) are the leading cause of death worldwide, with 14 million deaths per year attributable to a stroke…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Study shows high prevalence of hypertension among Indian children and teens
Hypertension is a hallmark risk factor for multiple cardiac diseases, making its detection and management crucial to long-term health. Increasingly,…
Acticor and University of Birmingham partner for heart attack drug trial
Acticor Biotech and the University of Birmingham in the UK have entered a collaboration to conduct a Phase IIb clinical trial of…
BMS seeks label expansion for FDA-approved Camzyos
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental new drug application for Camzyos (mavacamten)…
Pipeline Moves: positive topline results in pulmonary hypertension, genetic and metabolic disorders
This week on Pipeline Moves, we start with positive topline results from two Phase III trials in Alagille syndrome and pulmonary…
Milestone reports positive data from Phase III tachycardia therapy trial
Milestone Pharmaceuticals has reported positive topline findings from the Phase III RAPID clinical trial of its lead investigational product, etripamil, in paroxysmal…